Document is current

Article History

Received: 7 June 2024

Revised: 19 August 2024

Accepted: 30 September 2024

First Online: 14 October 2024

Declarations

:

: The authors declare no competing interests.

: This study was conducted in accordance with The Declaration of Helsinki. Informed consent was issued prior to treatment and patients were required to sign a consent form for participation and publication. All patients were over the age of 18 and alerted and oriented at the time of the procedure. The consent form outlined the risks associated with participating in this non-FDA approved experimental trial. We informed patients that they would need to follow-up at approximately 1 month, 6 months, 1 year, and then continue biannual total body exams including checking the site of the treatment. Participants were informed that if their skin cancer were to come back, they would need to have it surgically removed. We outlined all of the potential side effects of fractional laser treatment and the tirbanibulin ointment. We also reviewed and provided a separate handout summarizing the instructions of the ointment application simplified to maximize participant understanding and accuracy of the at-home application. The consent also included a media/data release statement that patients would allow their photos and data to be included in the study. The associated participant provided consent for publication of all figures displaying human images in this paper. This study was conducted in accordance with HIPAA regulations. Protected Health Information (PHI) was kept confidential during the entire process of the study and in any media or publications. Participants were closely tracked and monitored. No participants thus far have been lost to follow-up.